Chickenpox is a very common illness that almost all children catch before the age of five. For most it is a short illness with an itchy spotty rash but no long lasting effects, but some children will need admitting to hospital. There are very effective vaccines against chickenpox that are used in many other countries. We don’t use them in the UK because we don’t have enough information of the effects of having chickenpox on children and their families. This study collects data on children most severely affected by chickenpox to help decide if the vaccine should be used in the future.
A new vaccine has been developed by Sanofi Pasteur which may help to protect against four types of meningitis (“MenACYW”). All babies normally receive vaccines against meningitis type B (MenB) during infancy. This study will assess how well children’s immune systems respond to the MenACYW vaccine when this is given either at the same time or separately from the MenB vaccine and will monitor the safety of the vaccines. The new MenACYW vaccine is “investigational” meaning that it has been approved for use in the study, but it is not licensed for routine use. All participating babies will receive their routine vaccines as part of the study.
MET52 – ClinicalTrials.gov
Be on the TEAM
Teenagers and young children are at increased risk of diseases such as meningitis and blood poisoning due to bacteria called meningococcus. Most meningococcal disease in teenagers is due to Meningitis B (also known as MenB). We want to see if immunising teenagers with vaccines against MenB can reduce the number of teenagers carrying these bacteria in their throat. This would be important because it could mean that teenage MenB immunisation would not only help protect teenagers against these potentially deadly diseases, but also that babies, children and older adults are less likely to be exposed to the bacteria. In short, immunising teenagers with a MenB vaccine might mean lower rates of meningitis across all ages.
Be On The Team Website
What’s the Story?
The aim of this study is to help understand the ‘story’ of vaccine prevention of disease in the UK. To do this we are working with Public Health England to develop a new way of testing this by collecting blood samples from a selection of 0 to 24 year olds from across England. One of the ways vaccines protect us from infectious diseases is by stimulating our immune system to produce ‘antibodies’ in our blood. We would like to take blood samples from 2,300 children, teenagers, and young adults (20-24 years of age); to measure the antibody levels against important diseases, especially those that are vaccine preventable. This will help us understand how well the current vaccination programme is working; and, in particular, whether there are any age groups that are not so well protected. Studying this could help us work out if the UK is at risk of these vaccine preventable diseases re-appearing. We are interested in two diseases in particular: Meningococcal Group C (MenC) and Diphtheria.
What’s the STORY Website
MEDLEY is a clinical study researching an investigational medication for babies at high risk for respiratory syncytial virus (RSV) disease. The study is looking to see how safe the investigational medication is and if it works as well as a medication already approved for RSV.
MELODY is a clinical research study looking at an investigational medication to see how safe it is and whether it works to prevent respiratory syncytial virus (RSV) disease in healthy babies. The investigational medication has been looked at in previous clinical studies for RSV and there were no safety concerns in babies and adults.